Thursday, July 18, 2013
The Broad Institute of MIT and Harvard has
upgraded its original algorithm for cancer genome analysis to account for gene-specific
differences in mutation rates.1 Application of the improved
algorithm could help identify previously overlooked mutations, and in one type
of cancer it already allowed the researchers to narrow down the number of
Although advances in cancer genome
analysis will undoubtedly improve the quality of the catalog of
cancer-associated mutations, it may have little practical effect on the
industry's pursuit of cancer targets.
C. SciBX 6(27);
doi:10.1038/scibx.2013.676 Published online July, 18, 2013
1. Lawrence, M.S. et
al. Nature; published online June 16, 2013; doi:10.1038/nature12213 Contact:
Gad Getz, Broad Institute of MIT and Harvard, Cambridge, Mass. e-mail: firstname.lastname@example.org
Contact: Eric S. Lander, same affiliation as above e-mail: email@example.com
2. The Cancer Genome Atlas
Research Network. Nature 489, 519-525 (2012)
AND INSTITUTIONS MENTIONED
Blueprint Medicines, Cambridge, Mass.
Broad Institute of MIT and Harvard, Cambridge, Mass.
The Cancer Genome Atlas, Bethesda, Md.
H3 Biomedicine Inc., Cambridge, Mass.